Having validated the finding that PARP16 successfully regulated the cardiomyocytes hypertrophic response in vitro, we next sought to determine the impact of PARP16 on TAC-induced cardiac hypertrophy in vivo. The gene discussed is PARP16; the disease is cardiac hypertrophy.